Colistimethate

Các tên gọi khác (1) :

Colistin sodium methanesulfonate

Thuốc trị ký sinh trùng, chống nhiễm khuẩn

Thuốc Gốc

Small Molecule

CAS: 8068-28-8

ĐG : APP Pharmaceuticals , http://www.apppharma.com

CTHH: C₅₈H₁₀₅N₁₆O₂₈S₅

PTK: 1634.87

Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.

Nhận Dạng Quốc Tế & Đặc Tính Hóa Học

Công thức hóa học

C₅₈H₁₀₅N₁₆O₂₈S₅

Phân tử khối

1634.87

Monoisotopic mass

1633.588775306

InChI

InChI=1S/C58H110N16O28S5/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102)/p-5

InChI Key

InChIKey=BSSIRFLGSWHWDE-UHFFFAOYSA-I

IUPAC Name

[(3-{3-hydroxy-2-[2-(6-methyloctanamido)-4-[(sulfonatomethyl)amino]butanamido]butanamido}-3-{[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris({2-[(sulfonatomethyl)amino]ethyl})-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl)amino]methanesulfonate

Traditional IUPAC Name

SMILES

CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O

Độ hòa tan

Appreciable

logP

-17

logS

-2.6

pKa (strongest acidic)

-4.3

pKa (Strongest Basic)

6.46

PSA

706.71 Å²

Refractivity

370.19 m³·mol^-1

Polarizability

161.9 Å³

Rotatable Bond Count

H Bond Acceptor Count

H Bond Donor Count

Physiological Charge

-5

Number of Rings

Bioavailability

Dược Lực Học : Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Cơ Chế Tác Dụng : Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.

Dược Động Học :

▧ Absorption :
Very poor absorption from gastrointestinal tract.
▧ Metabolism :
As 80% of the dose can be recovered unchanged in the urine, and there is no biliary excretion, it can be assumed that the remaining drug is inactivated in the tissues, however the mechanism is unknown.
▧ Half Life :
2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.

Độc Tính : Oral LD₅₀ in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Chỉ Định : For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Tương Tác Thuốc :

Amikacin Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
Amphotericin B Amphotericin B may enhance the nephrotoxic effect of Colistimethate. Due to the potential for additive or synergistic nephrotoxicity between colistimethate and other nephrotoxic drugs, such as amphotericin B, this combination should be avoided whenever possible. If these agents must be used together, patients' renal function should be monitored closely.
Atracurium Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
Cisatracurium Besylate Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
Gentamicin Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
Kanamycin Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
Neomycin Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
Pancuronium Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
Rocuronium Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
Streptomycin Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
Tobramycin Increased risk of nephrotoxicity
Vancomycin Additive nephrotoxic effects may occur. Consider alternate therapy or monitor for renal function during concomitant therapy.
Vecuronium Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.

Liều Lượng & Cách Dùng : Powder, for solution - Intramuscular
Powder, for solution - Intravenous

Dữ Kiện Thương Mại

Giá thị trường

Biệt dược thương mại : Colistimethate For Injection 150 mg/vial

Giá bán buôn : USD >35.42

Đơn vị tính : ml
Biệt dược thương mại : Coly-Mycin S 3.3-3-10 mg/ml Suspension 5ml Bottle

Giá bán buôn : USD >49.17

Đơn vị tính : bottle
Biệt dược thương mại : Colistimethate 150 mg vial

Giá bán buôn : USD >57.0

Đơn vị tính : vial
Biệt dược thương mại : Coly-mycin m 150 mg vial

Giá bán buôn : USD >72.98

Đơn vị tính : vial

Nhà Sản Xuất

Công ty :

Sản phẩm biệt dược : Coly-Mycin M

Đóng gói

Công ty : APP Pharmaceuticals

Website : http://www.apppharma.com
Công ty : Ben Venue Laboratories Inc.

Website : http://www.benvenue.com
Công ty : Draxis Specialty Pharmaceuticals Inc.

Website : http://www.draxispharma.com
Công ty : JHP Pharmaceuticals LLC

Website : http://www.jhppharma.com
Công ty : Monarch Pharmacy

Website : http://www.monarch-pharmacy.co.uk
Công ty : Paddock Labs

Website : http://www.paddocklabs.com
Công ty : X-Gen Pharmaceuticals

Website : http://www.x-gen.us

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB01111

PubChem Compound

http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=216258

PubChem Substance

http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508586

KEGG Compound

http://www.genome.jp/dbget-bin/www_bget?cpd:C13553

KEGG Drug

http://www.genome.jp/dbget-bin/www_bget?drug:D02049

National Drug Code Directory

http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0574-0858-01

PharmGKB

http://www.pharmgkb.org/drug/PA164749509

RxList

http://www.rxlist.com/cgi/generic2/colistimethate.htm

Drugs.com

http://www.drugs.com/cdi/colistimethate.html

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading